Campath-1H therapy in refractory ocular inflammatory disease

A D Dick, P Meyer, T James, J V Forrester, G Hale, H Waldmann, J D Isaacs

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Background-Standard therapy for severe, immune mediated, ocular inflammation has significant side effects, and may fail to control the disease. T cell directed monoclonal antibody (mAb) therapy can provide long term remission of inflammatory disease in experimental models. The Campath-1H mAb was administered to patients with severe, refractory, ocular inflammation.

Methods-10 patients with severe, refractory, non-infectious ocular inflammatory disease were treated with Campath-1H mAb. This is a fully humanised mAb which recognises the pan-lymphocyte antigen CD52.

Results and discussion-Following Campath-1H therapy, all 10 patients showed an initial resolution of their ocular symptoms and signs. Long lasting remissions were achieved in eight patients, in whom baseline immunosuppression could subsequently be reduced to minimal levels. The possible mechanisms of action of Campath-1H therapy are discussed.

Original languageEnglish
Pages (from-to)107-109
Number of pages3
JournalBritish Journal of Ophthalmology
Volume84
Publication statusPublished - 2000

Keywords

  • MONOCLONAL-ANTIBODY THERAPY

Cite this

Dick, A. D., Meyer, P., James, T., Forrester, J. V., Hale, G., Waldmann, H., & Isaacs, J. D. (2000). Campath-1H therapy in refractory ocular inflammatory disease. British Journal of Ophthalmology, 84, 107-109.

Campath-1H therapy in refractory ocular inflammatory disease. / Dick, A D ; Meyer, P ; James, T ; Forrester, J V ; Hale, G ; Waldmann, H ; Isaacs, J D .

In: British Journal of Ophthalmology, Vol. 84, 2000, p. 107-109.

Research output: Contribution to journalArticle

Dick, AD, Meyer, P, James, T, Forrester, JV, Hale, G, Waldmann, H & Isaacs, JD 2000, 'Campath-1H therapy in refractory ocular inflammatory disease', British Journal of Ophthalmology, vol. 84, pp. 107-109.
Dick AD, Meyer P, James T, Forrester JV, Hale G, Waldmann H et al. Campath-1H therapy in refractory ocular inflammatory disease. British Journal of Ophthalmology. 2000;84:107-109.
Dick, A D ; Meyer, P ; James, T ; Forrester, J V ; Hale, G ; Waldmann, H ; Isaacs, J D . / Campath-1H therapy in refractory ocular inflammatory disease. In: British Journal of Ophthalmology. 2000 ; Vol. 84. pp. 107-109.
@article{6f6fd3b593af41ec948c408508f107a5,
title = "Campath-1H therapy in refractory ocular inflammatory disease",
abstract = "Background-Standard therapy for severe, immune mediated, ocular inflammation has significant side effects, and may fail to control the disease. T cell directed monoclonal antibody (mAb) therapy can provide long term remission of inflammatory disease in experimental models. The Campath-1H mAb was administered to patients with severe, refractory, ocular inflammation.Methods-10 patients with severe, refractory, non-infectious ocular inflammatory disease were treated with Campath-1H mAb. This is a fully humanised mAb which recognises the pan-lymphocyte antigen CD52.Results and discussion-Following Campath-1H therapy, all 10 patients showed an initial resolution of their ocular symptoms and signs. Long lasting remissions were achieved in eight patients, in whom baseline immunosuppression could subsequently be reduced to minimal levels. The possible mechanisms of action of Campath-1H therapy are discussed.",
keywords = "MONOCLONAL-ANTIBODY THERAPY",
author = "Dick, {A D} and P Meyer and T James and Forrester, {J V} and G Hale and H Waldmann and Isaacs, {J D}",
year = "2000",
language = "English",
volume = "84",
pages = "107--109",
journal = "British Journal of Ophthalmology",
issn = "0007-1161",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Campath-1H therapy in refractory ocular inflammatory disease

AU - Dick, A D

AU - Meyer, P

AU - James, T

AU - Forrester, J V

AU - Hale, G

AU - Waldmann, H

AU - Isaacs, J D

PY - 2000

Y1 - 2000

N2 - Background-Standard therapy for severe, immune mediated, ocular inflammation has significant side effects, and may fail to control the disease. T cell directed monoclonal antibody (mAb) therapy can provide long term remission of inflammatory disease in experimental models. The Campath-1H mAb was administered to patients with severe, refractory, ocular inflammation.Methods-10 patients with severe, refractory, non-infectious ocular inflammatory disease were treated with Campath-1H mAb. This is a fully humanised mAb which recognises the pan-lymphocyte antigen CD52.Results and discussion-Following Campath-1H therapy, all 10 patients showed an initial resolution of their ocular symptoms and signs. Long lasting remissions were achieved in eight patients, in whom baseline immunosuppression could subsequently be reduced to minimal levels. The possible mechanisms of action of Campath-1H therapy are discussed.

AB - Background-Standard therapy for severe, immune mediated, ocular inflammation has significant side effects, and may fail to control the disease. T cell directed monoclonal antibody (mAb) therapy can provide long term remission of inflammatory disease in experimental models. The Campath-1H mAb was administered to patients with severe, refractory, ocular inflammation.Methods-10 patients with severe, refractory, non-infectious ocular inflammatory disease were treated with Campath-1H mAb. This is a fully humanised mAb which recognises the pan-lymphocyte antigen CD52.Results and discussion-Following Campath-1H therapy, all 10 patients showed an initial resolution of their ocular symptoms and signs. Long lasting remissions were achieved in eight patients, in whom baseline immunosuppression could subsequently be reduced to minimal levels. The possible mechanisms of action of Campath-1H therapy are discussed.

KW - MONOCLONAL-ANTIBODY THERAPY

M3 - Article

VL - 84

SP - 107

EP - 109

JO - British Journal of Ophthalmology

JF - British Journal of Ophthalmology

SN - 0007-1161

ER -